1. Vinh DC, Embil JM: Rapidly progressive soft tissue infections. Lancet Infect Dis 5:501-513, 2005
2. Edelsberg J et al: Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 15:1516-1518, 2009
3. Celestin R et al: Erysipelas: A common potentially dangerous infection. Acta Dermatovenerol Alp Panonica Adriat 16:123-127, 2007
4. Damstra RJ et al: Erysipelas as a sign of subclinical primary lymphoedema: A prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg. Br J Dermatol 158:1210-1215, 2008
5. Wolfson JS, Sober AJ, Rubin RH: Dermatologic manifestations of infection in the compromised host. Annu Rev Med 34:205-217, 1983
6. Chira S, Miller LG: Staphylococcus aureus is the most common identified cause of cellulitis: A systematic review. Epidemiol Infect 138:313-317, 2010
7. Sendi P, Johansson L, Norrby-Teglund A: Invasive group B Streptococcal disease in non-pregnant adults: A review with emphasis on skin and soft-tissue infections. Infection 36:100-111, 2008
8. Karppelin M et al: Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: A prospective case-control study. Clin Microbiol Infect 16(6):729-734, 2010
9. Vayalumkal JV, Jadavji T: Children hospitalized with skin and soft tissue infections: A guide to antibacterial selection and treatment. Paediatr Drugs 8:99-111, 2006
10. Bocher S et al: Staphylococcus lugdunensis, a common cause of skin and soft tissue infections in the community. J Clin Microbiol 47:946-950, 2009
11. Garcia-Lechuz JM et al: Streptococcus pneumoniae skin and soft tissue infections: Characterization of causative strains and clinical illness. Eur J Clin Microbiol Infect Dis 26:247-253, 2007
12. Johansson L et al: Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans. Infect Immun 76:3399-3404, 2008
13. Kreikemeyer B, Klenk M, Podbielski A: The intracellular status of Streptococcus pyogenes: Role of extracellular matrix-binding proteins and their regulation. Int J Med Microbiol 294:177-188, 2004
14. Thulin P et al: Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med 3:e53, 2006
15. Mitchell PD et al: Panton-Valentine leukocidin-secreting Staphylococcus aureus causing severe musculoskeletal sepsis in children. A new threat. J Bone Joint Surg Br 89:1239-1242, 2007
16. Jacobus CH et al: Prevalence and demographics of methicillin resistant Staphylococcus aureus in culturable skin and soft tissue infections in an urban emergency department. BMC Emerg Med 7:19, 2007
17. David MZ et al: Predominance of methicillin-resistant Staphylococcus aureus among pathogens causing skin and soft tissue infections in a large urban jail: Risk factors and recurrence rates. J Clin Microbiol 46:3222-3227, 2008
18. Tejeda-Ramirez E, Behani M, Leggiadro RJ: Community-associated methicillin-resistant staphylococcal infection in an inner city hospital pediatric inpatient population. South Med J 102:135-138, 2009
19. Rice LB: Antimicrobial resistance in Gram-positive bacteria. Am J Infect Control 34:S11-S19; discussion S64-S73, 2006
20. Kirkland EB, Adams BB: Methicillin-resistant Staphylococcus aureus and athletes. J Am Acad Dermatol 59:494-502, 2008
21. Antoniou T et al: Prevalence of community-associated methicillin-resistant Staphylococcus aureus colonization in men who have sex with men. Int J STD AIDS 20:180-183, 2009
22. Popovich KJ, Hota B: Treatment and prevention of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Dermatol Ther 21:167-179, 2008
23. Shittu A et al: Isolation and molecular characterization of multiresistant Staphylococcus sciuri and Staphylococcus haemolyticus associated with skin and soft-tissue infections. J Med Microbiol 53:51-55, 2004
24. Mombach Pinheiro Machado AB et al: Distribution of staphylococcal cassette chromosome mec (SCCmec) types I, II, III and IV in coagulase-negative staphylococci from patients attending a tertiary hospital in southern Brazil. J Med Microbiol 56:1328-1333, 2007
25. Davis SL et al: Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 45:1705-1711, 2007
26. Shorr AF: Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: Review and analysis of the literature. Pharmacoeconomics 25:751-768, 2007
27. Hulten KG et al: Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001–2007. Infect Control Hosp Epidemiol 31:183-190, 2010
28. Sdougkos G et al: Community-associated Staphylococcus aureus infections and nasal carriage among children: Molecular microbial data and clinical characteristics. Clin Microbiol Infect 14:995-1001, 2008
29. Patel M: Community-associated meticillin-resistant Staphylococcus aureus infections: Epidemiology, recognition and management. Drugs 69:693-716, 2009
30. Patel JB, Gorwitz RJ, Jernigan JA:
Mupirocin resistance.
Clin Infect Dis 49:935-941, 2009
31. Batra R et al: Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. Clin Infect Dis 50:210-217, 2010
32. Jones JC et al:
Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit.
Clin Infect Dis 45:541-547, 2007
33. Mutnick AH, Enne V, Jones RN:
Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.
Ann Pharmacother 37:769-774, 2003
34. Zirakzadeh A, Patel R: Vancomycin-resistant enterococci: Colonization, infection, detection, and treatment. Mayo Clin Proc 81:529-536, 2006
35. Sood S et al: Enterococcal infections & antimicrobial resistance. Indian J Med Res 128:111-121, 2008
36. Hook EW 3rd et al: Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 146:295-297, 1986
37. Lopez FA, Lartchenko S: Skin and soft tissue infections. Infect Dis Clin North Am 20:759-772, v-vi, 2006
38. Chong FY, Thirumoorthy T: Blistering erysipelas: Not a rare entity. Singapore Med J 49:809-813, 2008
39. Garner JS et al: CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128-140, 1988
40. El Karoui K et al: Escherichia coli extensive cellulitis after laparoscopic radical prostatectomy. Urology 72:778-779, 2008
41. Bluestein D, Javaheri A: Pressure ulcers: Prevention, evaluation, and management. Am Fam Physician 78:1186-1194, 2008
42. Brook I: Management of human and animal bite wounds: An overview. Adv Skin Wound Care 18:197-203, 2005
43. Conlon HA: Human bites in the classroom: Incidence, treatment, and complications. J Sch Nurs 23:197-201, 2007
44. Koster JB, Kullberg BJ, van der Meer JW: Recurrent erysipelas despite antibiotic prophylaxis: An analysis from case studies. Neth J Med 65:89-94, 2007
45. Kroshinsky D, Grossman ME, Fox LP: Approach to the patient with presumed cellulitis. Semin Cutan Med Surg 26:168-178, 2007
46. Falagas ME, Vergidis PI: Narrative review: Diseases that masquerade as infectious cellulitis. Ann Intern Med 142:47-55, 2005
47. Laube S, Farrell AM: Bacterial skin infections in the elderly: Diagnosis and treatment. Drugs Aging 19:331-342, 2002
48. Eron LJ, Lipsky BA: Use of cultures in cellulitis: When, how, and why? Eur J Clin Microbiol Infect Dis 25:615-617, 2006
49. Sachs MK: The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 150:1907-1912, 1990
50. Swartz MN: Clinical practice. Cellulitis. N Engl J Med 350:904-912, 2004
51. Brook I, Frazier EH: Clinical features and aerobic and anaerobic microbiological characteristics of cellulitis. Arch Surg 130:786-792, 1995
52. Lazzarini L et al: Erysipelas and cellulitis: Clinical and microbiological spectrum in an Italian tertiary care hospital. J Infect 51:383-389, 2005
53. Mills AM, Chen EH: Are blood cultures necessary in adults with cellulitis? Ann Emerg Med 45:548-549, 2005
54. Peralta G et al: Risk factors for bacteremia in patients with limb cellulitis. Eur J Clin Microbiol Infect Dis 25:619-626, 2006
55. Bernard P et al: Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol 125:779-782, 1989
56. Chao HC et al: Sonographic evaluation of cellulitis in children. J Ultrasound Med 19:743-749, 2000
57. Hsiao CB et al: Staphylococcus aureus antimicrobial susceptibility of abscess samples from adults and children from the Kaleida Health System in western New York State, 2003–2006. J Clin Microbiol 48(5):1753-1757, 2010
58. Goldstein EJ et al: Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of
moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.
J Med Microbiol 57:452-456, 2008
59. Phillips S, MacDougall C, Holdford DA: Analysis of empiric antimicrobial strategies for cellulitis in the era of methicillin-resistant Staphylococcus aureus. Ann Pharmacother 41:13-20, 2007
60. Elliott DJ et al: Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. Pediatrics 123:e959-e966, 2009
61. Madaras-Kelly KJ et al: Efficacy of oral beta-lactam versus non-beta-lactam treatment of uncomplicated cellulitis. Am J Med 121:419-425, 2008
62. Pokharna H, Haque N, Zervos M:
Vancomycin vs beta-lactam – drug of choice for empiric treatment of cellulitis requiring hospitalization.
Abstract 1238 in Infectious Diseases Society of America 48th Annual Meeting, Oct 23, 2010
63. Fish DN:
Meropenem in the treatment of complicated skin and soft tissue infections.
Ther Clin Risk Manag 2:401-415, 2006
64. Beibei L et al:
Linezolid versus
vancomycin for the treatment of Gram-positive bacterial infections: Meta-analysis of randomised controlled trials.
Int J Antimicrob Agents 35:3-12, 2010
65. De Cock E et al: Cost-effectiveness of
linezolid versus
vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
Med Mal Infect 39:330-340, 2009
66. Bliziotis IA et al:
Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: A meta-analysis.
Ann Pharmacother 44:97-106, 2010
67. Silverman JA, Perlmutter NG, Shapiro HM: Correlation of
daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.
Antimicrob Agents Chemother 47:2538-2544, 2003
68. Ziglam H:
Daptomycin and
tigecycline: A review of clinical efficacy in the antimicrobial era.
Expert Opin Pharmacother 8:2279-2292, 2007
69. Bailey J, Summers KM:
Dalbavancin: A new lipoglycopeptide antibiotic.
Am J Health Syst Pharm 65:599-610, 2008
70. Crandon J, Nicolau DP:
Oritavancin: A potential weapon in the battle against serious Gram-positive pathogens.
Future Microbiol 3:251-263, 2008
71. Attwood RJ, LaPlante KL:
Telavancin: A novel lipoglycopeptide antimicrobial agent.
Am J Health Syst Pharm 64:2335-2348, 2007
72. Zhanel GG et al: Ceftaroline: A novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 69:809-831, 2009
73. Anderson SD, Gums JG:
Ceftobiprole: An extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Ann Pharmacother 42:806-816, 2008
74. Stevens DL: Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. J Infect 59(Suppl 1):S32-S39, 2009
75. Ardanuy C et al: Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993–2008). J Antimicrob Chemother 65:634-643, 2010
76. Myers AL et al: Genetic commonality of macrolide-resistant group A beta hemolytic streptococcus pharyngeal strains. Ann Clin Microbiol Antimicrob 8:33, 2009
77. Loeb M et al: Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev (4):CD003340, 2003
78. Schaffer
AC, Lee JC: Staphylococcal vaccines and immunotherapies.
Infect Dis Clin North Am 23:153-171, 2009
78. Schaffer
AC, Lee JC: Vaccination and passive immunisation against Staphylococcus aureus.
Int J Antimicrob Agents 32(Suppl 1):S71-S78, 2008
79. McMillan DJ, Chhatwal GS: Prospects for a group A streptococcal vaccine. Curr Opin Mol Ther 7:11-16, 2005